Table 1.
Baseline characteristics of patients
| All centers (n=437) |
Virginia (n=230) |
Ohio (n=107) |
Arkansas (n=100) |
p* | |
|---|---|---|---|---|---|
| Age | 57 ± 8 | 57 ± 7 | 58 ± 11 | 56 ± 7 | 0.4 |
| Sex (male) | 64% | 74% | 59% | 46% | <0.001 |
| Etiology | |||||
| HCV | 54% | 50% | 30% | 87% | <0.001 |
| Alcohol | 15% | 19% | 20% | 2% | |
| NASH | 19% | 23% | 26% | 4% | |
| Other | 12% | 9% | 24% | 7% | |
| MELD | 11 ± 5 | 13 ± 6 | 10 ± 4 | 10 ± 3 | <0.0001 |
| Prior OHE | 36% | 41% | 30% | 30% | 0.05 |
| OHE Treatment | |||||
| Lactulose | 69% | 80% | 26% | 59% | |
| Rifaximin | 7% | 5% | 11% | 9% | <0.001 |
| Both | 24% | 15% | 63% | 32% | |
*
Refers to comparison across patients included in Virginia, Ohio, and Arkansas. HCV: hepatitis C virus, MELD: model for end-stage liver disease, NASH: non-alcoholic steatohepatitis, OHE: overt hepatic encephalopathy